Latest Breaking News On - Algernon pharmaceuticals inc - Page 1 : comparemela.com

Algernon Pharmaceuticals Inc (OTCMKTS:AGNPF) Short Interest Update

Algernon Pharmaceuticals Inc (OTCMKTS:AGNPF) Short Interest Update
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Algernon pharmaceuticals incAlgernon pharmaceuticalsNews ratings for algernon pharmaceuticals dailyAlgernon pharmaceuticals price performanceGet free reportPharmaceuticals incAlgernon pharmaceuticals daily

Algernon NeuroScience and the Centre for Human Drug

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT:.

Noord hollandUnited kingdomBritish columbiaChristopherj moreauRick strassmanAlgernon pharmaceuticals incConstraint induced movement therapyAlgernon pharmaceuticalsCentre for human drug researchSeyltx incInterdisciplinary conference on psychedelic researchCompany phaseAlgernon neuroscienceHuman drug researchInterdisciplinary conferencePsychedelic research

Algernon Pharmaceuticals CEO Christopher J Moreau to Be Featured on Radius Research s Pitch, Deep Dive and Q&A Webinar on April 16th, 2024 - Algernon Pharmaceuticals (OTC:AGNPF)

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF), is pleased to invite investors and other interested

United kingdomBritish columbiaMartin gagelChristopherj moreauAlgernon pharmaceuticalsCompany or algernonNeither the canadian securities exchangeRadius research pitchMarket radius capital incMarket radius researchCanadian securities exchangeAlgernon pharmaceuticals incSeyltx incMarket radiusDeep diveRegistration link

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it plans to move forward with its intravenous formulation of its AP-188 (“N,N-Dimethyltryptamine” or “DMT”) stroke research program as its lead asset, after having sold its Ifenprodil research program for USD $2M cash and a 20% common share

British columbiaUnited kingdomChristopherj moreauCompany or algernonAlgernon pharmaceuticalsAlgernon pharmaceuticals incCentre for human drug researchCompany phaseAlgernon neuroscienceStroke studyHuman drug researchAlgernon pharmaceuticals incClinical trial designResearch programAlgernon neuroscience

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U S Based Seyltx for USD $2M and a 20% Equity Position

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U S Based Seyltx for USD $2M and a 20% Equity Position
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesBritish columbiaUnited kingdomDietricha stephanChristopherj moreauAlgernon ifenprodilMaxim groupCanadian securities exchangeNeither the canadian securities exchangeAlgernon pharmaceuticals announces closing of the acquisitionMerck coAlgernon pharmaceuticalsDrug administrationNo securities exchangeBellus healthAfferent pharmaceuticals